Authors

Latest:

O'Neil on the Feasibility of Diagnostic CT-Enabled Planning For Patients Receiving Palliative Radiation Therapy

Melissa O'Neil, MRT(T), discusses findings from the randomized phase 2 Diagnostic CT-Enabled Radiation Therapy trial of palliative radiation therapy.

Nicole S. Evans, MD

Latest:

Dr Evans on the Influence on Patient Factors and Treatment Decisions in Pancreatic Cancer

Nicole S. Evans, MD, discusses the influence of patient factors on declining treatment in pancreatic cancer.

Brian Hill, MD, PhD, Cleveland Clinic

Latest:

Dr. Hill and Dr. Sauter Consider CAR T-Cell Therapy in Second-Line Setting for DLBCL

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.

Aditya Bardia, MD

Latest:

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.

Rafi Kabarriti, MD

Latest:

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

Guru Subramanian Guru Murthy, MD, MS

Latest:

Dr. Murthy on the Potential Benefits of Treatment De-Escalation in Ph+ B-ALL

Guru Subramanian Guru Murthy, MD, MS, discusses the potential benefits of treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Jason Abdou Mouabbi, MD

Latest:

Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular Carcinoma

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

Yuliya Linhares, MD

Latest:

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).

Sanjay Goel, MD, MS

Latest:

Dr Goel on the Safety Profile of Tinengotinib in Solid Tumors

Sanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.

Minoo Battiwalla, MD

Latest:

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management

Minoo Battiwalla, MD, MS, discusses how emerging therapies contribute to the management of aggressive variants of follicular lymphoma.

Raj Singh, MD

Latest:

Dr Singh on Unmet Medical Needs in Lung Cancer Treatment

Raj Singh, MD, discusses unmet medical needs in the treatment of patients with lung cancer.

Peter Gibbs, MBBS, MD, FRACP,

Latest:

Dr. Gibbs on the Role of ctDNA in Predicting Distant vs Locoregional Recurrence in CRC

Peter Gibbs, MBBS, MD, FRACP, discusses the role of circulating tumor DNA in predicting distant vs locoregional recurrence in colorectal cancer.

Javier Martin-Broto, MD, PhD

Latest:

Dr Martín-Broto on the Efficacy of Sunitinib Plus Nivolumab in Clear Cell Sarcoma

Javier Martín Broto MD, PhD, discusses the efficacy of treatment with sunitinib plus nivolumab in clear cell sarcoma, according to the IMMUNOSARC II trial.

Biagio Ricciuti, MD

Latest:

Dr Ricciuti on PD-L1 Expression and Long-Term Survival Outcomes With PD-L1 Inhibitors in Advanced NSCLC

Biagio Ricciuti, MD, discusses the association between PD-L1 expression levels and long-term survival with anti–PD-L1 monotherapy in patients with advanced non–small cell lung cancer.

Amar U. Kishan, MD

Latest:

Dr. Kishan on the MIRAGE Trial of MRI-Guided SBRT in Prostate Cancer

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

Onclive Team

Latest:

Cytokines Play Integral Role in Cancer Immune Cycle

In the setting of cancer, cytokines contribute to cells’ antitumor response, cell damage, inflammation, angiogenesis, metastasis, and other cellular processes that enable tumor survival

A. Craig Lockhart, MD, MHS

Latest:

Dr. Lockhart on Dual-Immunotherapy Strategies in CRC

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).

A. Daniel Pinheiro, MD

Latest:

Dr. Pinheiro on Determinants of Cost in the Treatment of T1-T3 Oropharynx Cancer

A. Daniel Pinheiro, MD, physician, Otolaryngology, Mercy Clinic, discusses a study looking at the determinants of cost in the treatment of patients with T1 to T3 oropharynx cancer.

A. David McCollum, MD

Latest:

Dr. McCollum on the Clinical Utility of Regorafenib in mCRC

A. David McCollum, MD, attending oncologist, Baylor University Medical Center, discusses the clinical utility of regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).